近日，新西兰疫苗咨询中心（The Immunisation Advisory Center）发布公告，

建议在中国接种了无效疫苗的孩子，在新西兰重新接种疫苗。

全文翻译如下：

Two batches of DTaP vaccine were recalled by the China Food and Drug Administration (CFDA) on October 29, 2017 after failing potency testing. This issue is one of vaccine potency, not vaccine safety i.e. the vaccines are not expected to have caused any harm but may have not induced a protective immune response.

中国食品药品监督管理局（CFDA）在2017年10月29日召回了两批无细胞百白破疫苗，这两批疫苗没能通过效能测试。这些疫苗不会对接种对象造成任何伤害，但可能无法激活保护性免疫，也就是说被注射者无法获得相应的免疫力。

None of these vaccines were distributed within New Zealand.

这些问题疫苗没有进入新西兰。

Please consider DTaP vaccines administered to children from March to October 2017 in Hebei, Shandong and Chongqing provinces to be invalid. The Ministry of Health and IMAC advises these children should be offered re-vaccination, if requested, as per catch up recommendations. Serology testing is not required to determine a child’s immune status prior to offering re-vaccination. Should parents wish to have an additional dose of the vaccine, there are no significant safety concerns associated with receiving an additional dose, although children may have an increased local reaction such as redness or swelling at the vaccination site.

从2017年3月至10月，在河北、山东和重庆三省接种的无细胞百白破疫苗都被认为是无效的。新西兰卫生部和免疫咨询中心（IMAC）建议这些孩子重新接种疫苗。重新接种疫苗前，孩子不需要进行血清检测来确定其免疫状态。虽然孩子有可能出现局部不良反应，比如在接种部位发红或肿胀，但是额外剂量的疫苗不会对孩子产生明显的安全问题。

To work out if an additional dose is required please consider the child’s current age and the number of previous doses of DTaP received as per Appendix 2 of the Immunisation Handbook.

请考虑孩子目前的年龄情况和疫苗接种手册附录2中所记录的历史接种信息，以决定是否要给孩子补种疫苗。

It is likely that the only age groups of children impacted would be those between approximately 3 months and 24 months of age at the time they were immunised in China, given the vaccine schedule used there and allowing for late administration.

考虑到中国接种疫苗的实际情况，在出生3个月和24个月之间，在中国接种疫苗的儿童，很有可能是接种了无效的疫苗。

Should a child need re-vaccination, the vaccines to be used would be those included on the NZ Immunisation Schedule i.e. DTaP-IPV-HepB/Hib (Infanrix Hexa®) or DTaP-IPV (Infanrix-IPV).

儿童如果确定需要重新接种疫苗，那么将被重新接种新西兰免疫接种计划中的无细胞百白破联合疫苗，即DTaP-IPV-HepB/Hib（Infanrix Hexa®）或DTaP-IPV（Infanrix IPV）。

If the child’s overseas vaccinations were entered onto the NIR, and these doses need to be repeated, they should be noted as ‘invalid’. Invalidating doses will require a phone call or fax to your NIR administrator. The new doses are entered as per usual onto the PMS, and messaged through to the NIR.

如果儿童在海外接种的疫苗在国家免疫登记处（National Immunisation Register）的清单上，那么这些疫苗应该是“无效”的，需要重新注射。可以通过电话或者传真联系国家免疫登记处（NIR）监管员，以确认疫苗是否属于无效。疫苗重新注射后将在操作管理系统（Practice Management System）进行记录，并报备给国家免疫登记处（NIR）。

As there is a large amount of vaccine given within China, the batches of concern are an extremely small portion of all vaccines delivered and we expect the number of children in NZ requiring revaccination to be limited.

失效批次疫苗在中国全部所交付的疫苗当中只占很小的一部分比例，因此我们认为在新西兰需要复种疫苗的儿童人数是有限的。